Clinical trial NCT06818955: Orlistat Overcoming Third-generation EGFR-TKI Resistance
Official title: Clinical Study on the Safety and Efficacy of Orlistat in Third-generation EGFR-TKI Resistance
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Lung Adenocarcinoma
Osimertinib
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
Collaborators: name: Hubei Cancer Hospital
First posted: 2025-02-11
Enrollment: 36
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: EGFR mutation positivity accounts for 50% of lung adenocarcinoma cases. Multiple clinical trials, represented by FLAURA, AENEAS, and FURLONG studies, have confirmed that third-generation EGFR-TKI can provide significant benefits to patients with EGFR sensitive mutations and has become the first-line preferred treatment for EGFR mutation positive NSCLC, with a median PFS of around 19 and OS of around 38 months. These large-scale Phase III studies have confirmed the excellent efficacy of third-generation EGFR-TKI in EGFR mutation positive patients. However, regardless of the targeted drug, resistance will occur within less than 2 years. Blood test data for first-line treatment with osimertinib showed that the most common forms of resistance were secondary MET amplification (20%), EGFR C797S mutation (8%), PIK3CA, Her-2 amplification, and so on. The mechanism of resistance is complex and has many factors. Currently, for the treatment of third-generation EGFR-TKI resistance, the IMPOWER150 and ORIENTAL31 treatment modes are commonly used. Although the combination of these four drugs has good efficacy, the side effects are significant. Some patients are unwilling to undergo chemotherapy due to physical problems and hope to continue taking targeted drugs orally. Orlistat is a long-acting and potent specific gastrointestinal lipase inhibitor that can directly block the absorption of body fat. It is commonly used for weight loss in clinical practice and is relatively inexpensive. Our project team found in vitro and in vivo data that orlistat can effectively promote sensitivity to osimertinib. The combination of orlistat and osimertinib can overcome osimertinib resistance without significant toxic side effects. For patients who are unwilling to undergo chemotherapy and require continued oral targeted therapy, the investigators attempted to add orlistat to see if it can improve resistance.


Eligibility criteria: Inclusion Criteria:

1. Previously received three generations of systemic TKI treatment and developed resistance (including Axitinib, Amitinib, Fumatinib, Bevatinib, Lazetinib, etc.);
2. General condition score ECOG 0-2 points;
3. Expected survival period of more than 3 months;
4. Laboratory examination:

   ① WBC≥3.5×109／L，ANC≥1.5×109／L，PLT≥80×109／L， Hb≥90g/L；

   ② Blood BUN and creatinine are within 1.5 times the upper limit of normal values;

   ③ TBIL ≤ 1.5 times the upper limit of normal value;

   ④ ALT and AST ≤ 2.5 times the upper limit of normal values; Patients with liver metastasis should not exceed 5 times the upper limit of normal values;

   ⑤ Normal coagulation function (PT, APTT within 1.5 times the upper limit of normal range).
5. The patient requests to continue taking targeted drugs orally
6. Voluntarily sign the informed consent form, with expected compliance.

Exclusion Criteria:

1. Suffering from serious medical diseases, including serious heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, serious infection, and active gastrointestinal ulcer;
2. A large amount of pleural and pericardial effusion requires immediate treatment;
3. Brain metastases with clinical symptoms;
4. Pregnant or lactating women;
5. The patient is able to tolerate chemotherapy and is willing to accept it

Primary outcomes:
measure: ORR
timeFrame: At the end of cycle 3 (each cycle is 21 days)
Secondary outcomes:
measure: Safety (Rate of grade 3 and higher grade treatment-related adverse events)
timeFrame: From date of treatment allocation until treatment completion 30 days
Other outcomes:
Locations:
Study officials:
References: